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Abstract
The monocarboxylate transporter 1 (MCT1 or SLC16A1) is a carrier of short-chain fatty acids, ketone bodies, and lactate in
several tissues. Genetically modified C57BL/6J mice were produced by targeted disruption of the mct1 gene in order to
understand the role of this transporter in energy homeostasis. Null mutation was embryonically lethal, but MCT1+/2 mice
developed normally. However, when fed high fat diet (HFD), MCT1+/2 mice displayed resistance to development of diet-
induced obesity (24.8% lower body weight after 16 weeks of HFD), as well as less insulin resistance and no hepatic steatosis
as compared to littermate MCT1+/+ mice used as controls. Body composition analysis revealed that reduced weight gain in
MCT1+/2 mice was due to decreased fat accumulation (50.0% less after 9 months of HFD) notably in liver and white adipose
tissue. This phenotype was associated with reduced food intake under HFD (12.3% less over 10 weeks) and decreased
intestinal energy absorption (9.6% higher stool energy content). Indirect calorimetry measurements showed, 15% increase
in O2 consumption and CO2 production during the resting phase, without any changes in physical activity. Determination of
plasma concentrations for various metabolites and hormones did not reveal significant changes in lactate and ketone
bodies levels between the two genotypes, but both insulin and leptin levels, which were elevated in MCT1+/+ mice when fed
HFD, were reduced in MCT1+/2 mice under HFD. Interestingly, the enhancement in expression of several genes involved in
lipid metabolism in the liver of MCT1+/+ mice under high fat diet was prevented in the liver of MCT1+/2 mice under the same
diet, thus likely contributing to the observed phenotype. These findings uncover the critical role of MCT1 in the regulation
of energy balance when animals are exposed to an obesogenic diet.
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Introduction
Short-chain monocarboxylates such as lactate or the ketone
bodies ß-hydroxybutyrate and acetoacetate are metabolic sub-
strates that play crucial roles in body energy homeostasis under
various conditions (e.g. exercise or fasting). Indeed, lactate
represents an important oxidative energy substrate for various
tissues such as the heart [1], the brain [2] or the oxidative fibers of
muscles [3]. Moreover, lactate is used by the liver for gluconeo-
genesis, as part of the Cori cycle [4]. Lactate also regulates both
food intake and blood glucose levels by acting directly on fuel-
sensitive neurons in the hypothalamus [5–7]. In parallel, ketone
bodies produced during periods of fasting or under high fat diets
[8,9] are used as energy substrates by several tissues including the
brain [10], the heart [11] and skeletal muscles [12]. Ketone bodies
have also been shown to affect food intake [13] and body weight
gain [14]. From a clinical point of view, it has been suggested that
both lactate [15] and ketone bodies [16] metabolism could play an
important role in the development of obesity although the
underlying mechanisms remain obscure.
Interestingly, lactate and ketone bodies share common mem-
brane transporters. A restricted group of carriers has been
identified and its members are collectively known as monocarbox-
ylate transporters or MCTs. They belong to the SLC16 protein
family and consist of four H+-linked transporters termed MCT1-4
[17]. The first member, MCT1 (or SLC16A1), has the broadest
tissue distribution. It is abundant in brain, heart, muscle, liver and
kidney and it is also expressed in important tissues for energy
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homeostasis such as adipose tissue and gut [17–19]. At the cellular
level, it can exhibit a specific and differential expression pattern. In
skeletal muscle for example, it is particularly enriched in oxidative
fibers [20]. MCT1 expression has been shown to be essential for
monocarboxylate utilization in these different tissues and cell
types. For the moment however, it is difficult to understand the
importance of monocarboxylate exchange and utilization for the
integrated regulation of body energy homeostasis without an
appropriate in vivo model. In order to gain insight on this issue, a
transgenic mouse model was generated in which the mct1 gene was
invalidated. The resulting metabolic phenotype of the haploinsuf-
ficient MCT1+/2 mouse suggests a key role of this transporter in
the regulation of body weight and fat accumulation, particularly
upon exposure to an obesogenic diet.
Materials and Methods
Ethics statement
Animal experiments were performed in accordance with the
Swiss animal welfare laws under the authorization nu VD 2252
from the Service de la consommation et des affaires ve´te´rinaires du
Canton de Vaud, Switzerland.
Knockin targeting construct and generation of MCT1
knockout/LacZ knockin mice
Heterozygote MCT1 knockout/LacZ knockin mice (referred to
as MCT1+/2 or MCT1+/LacZ mice) were generated by targeted
homologous recombination. A targeting construct was made by
fusing the thymidine kinase (TK) gene sequence with 1600 base
pairs (bp) of the mouse genomic sequence (129/OlaHsd strain)
ending with part of the first exon containing the translation
initiation codon of the MCT1 gene (Fig. 1A). Then from the start
codon, 640 bp of the MCT1 gene containing exon 1 and part of
the first intron were replaced by the LacZ gene sequence fused
with a neomycin (Neo) resistance gene sequence and put in frame
with the MCT1 promoter. The targeting construct was completed
with the following 5800 bp of the MCT1 genomic sequence
starting from the middle of the first intron until the stop codon of
MCT1 gene sequence. This construct was cloned in the pGEM-T-
easy vector (Promega, Wallisellen, Switzerland). Before electropo-
ration into mouse embryonic stem (ES) cells (from 129 OlaHsd
strain), the vector was linearized by digestion with SacII (Roche
Diagnostics, Rotkreuz, Switzerland). ES cells with proper sequence
integration were selected by adding gancyclovir and G418 in ES
cell culture medium for negative and positive selection, respec-
tively [21]. A total of 704 neomycin resistant ES clones were tested
by PCR for the presence of the targeting construct into the
genome. Primer sequences were chosen to span the upstream
genomic sequence serving for recombination. Four ES clones were
found positive and tested further by Southern blot analysis. DNA
was purified from the PCR positive clones, and digested with NdeI
(Roche Diagnostics, Rotkreuz, Switzerland) before being pro-
cessed by normal Southern blot procedure (Fig. 1B). A 900 bp
genomic sequence, not contained in the targeting construct, was
chosen as Southern probe to test ES DNA clones that have
undergone a correct double recombination event. Cells from a
positive ES clone were injected into 106 blastocysts (C57BL/6).
Blastocysts were implanted into foster mothers. Among the 29
newborns obtained, 8 presented a chimeric fur (agouti pigmen-
tation). Two chimeric males were crossed with C57BL/6 females.
DNA extracted from F1 agouti (50% 129Ola, 50% C57BL/6)
offsprings was tested by PCR and Southern blot for the presence of
the modified allele. Electroporation in ES cells, selection of
positive clones, transfer into blastocysts and implantation, as well
as viable chimeric mouse selection were performed by genOway
(Lyon, France, info@genoway.com). Animal breeding was per-
formed by Charles River (L’Arbresle Cedex, France). F1 progeny
carrying the transgene was backcrossed for 8 generations onto the
C57BL/6 background. Subsequently, heterozygous MCT1 knock-
out/LacZ knockin males and females were crossed for character-
ization of all resulting genotypes. Mice were genotyped by PCR
with a combination of 3 primers (ßGalRe GATTAAGTTGGG-
TAACGCCAG, MCT1Fo3962 GTGTCACCCAACACTGA-
TAACAAGAG; MCT1Re4500 TGATACTTCACTGGTCG-
TTGCA), giving rise to a 535 bp wild type fragment and a 422
bp knockin fragment. The official name of the mutant mouse
following the guidelines of the international committee of
standardized genetic nomenclature for mice (http://www.
informatics.jax.org/mgihome/nomen/gene.shtml) is:
B6.129OlaHsd-MCT1tm(lacZ)Syle.
Animals
MCT1+/2 mice on the C57BL/6J genetic background were
bred to produce heterozygous (MCT1+/2) mice and wildtype
(MCT1+/+) littermate controls. Male mice were sent by Charles
River (L’Arbresle Cedex, France) at 4 weeks of age. All animals
were housed in cages placed in a controlled environment room,
with a constant temperature of 20–22uC, relative moisture 50-60%
and 12h light-dark cycle. Mice were allowed free access to food
and water.
ß-Galactosidase histological staining
Mouse tissue cryosections were put onto Superfrost Plus slides
(Thermo scientific, Braunschweig, Germany) and allowed to dry at
room temperature for 10 minutes. Then they were washed once
with 1x Phosphate Buffer Saline (PBS) solution. An X-Gal staining
solution (potassium ferricyanide (C6FeK3) 5 mM, potassium
ferrocyanide (C6FeK4) 5 mM, 200 ml of X-Gal solution at
50 mg/ml (Promega, Wallisellen, Switzerland; cat Nu V394A) in
10 ml PBS solution) was added onto tissue sections. The slides
were incubated for 15 hours at 37uC. To avoid evaporation, slides
were placed in a H2O saturated incubator. The box containing the
slides was wrapped with aluminium foil to protect from light. Then
tissue sections were washed once with 1x PBS solution, then fixed
for 15 minutes with 4% paraformaldehyde solution and washed
once with 1x PBS solution. Tissue sections were counterstained
with nuclear fast red solution (Sigma, Buchs, Switzerland; cat Nu
N3020), then dehydrated and mounted with Eukitt solution
(Kindler, Freiburg, Germany).
Quantitative RT-PCR and Western blots
Mice were deeply anesthetized using sodium pentobarbital and
transcardially perfused with cooled saline (0.9% NaCl + heparin
10 units/ml). Various tissues were rapidly collected and frozen in
liquid nitrogen. Frozen tissues were ground into a fine powder
using a mortar and pestle. To avoid RNA and protein
degradation, we began our tissue collection by taking first pancreas
and liver. Each tissue sample was divided in two to extract
separately RNA and proteins. mRNA was extracted using the
RNeasy mini kit (Qiagen, Basel, Switzerland; Cat Nu 74104)
following manufacturer’s instructions. Tissue samples were
homogenized with the QIAshredder (Qiagen, Basel, Switzerland;
Cat Nu 79654) column before mRNA purification. For protein
extraction, 40 mg of tissue powder were dissolved in buffer A
(30 mM HEPES, 210 mM sucrose, 40 mM NaCl, 2 mM EGTA,
1% SDS, Protease inhibitors). Samples of protein extracts were
then centrifuged at 12’000 RPM for 5 min. The protein
supernatant was used for gel electrophoresis.
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Quantification of mRNA was performed with the Nanodrop
ND-1000 apparatus (Witec, Littau, Switzerland). One hundred ng
of mRNA in a volume of 25 ml were reverse transcribed using the
RT High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Rotkreuz, Switzerland). Quantitative real-time PCR analysis was
performed with the Applied Biosystems 7900 (Applied Biosystems,
Rotkreuz, Switzerland) Real-Time PCR System. The Taq
polymerase master mix employed was the Power SYBR Green
(Applied Biosystems, Rotkreuz, Switzerland). Primer sequences
used for MCT1 (NM_009196) mRNA quantification were
mMCT1Fo1361 AATGCTGCCCTGTCCTCCTA mMCT1Re-
1441 CCCAGTACGTGTATTTGTAGTCTCCAT, and for ß-
actin (NM_007393) mActinßFo31 GCTTCTTTGCAGCTCC-
TTCGT mActinßRe94 ATATCGTCATCCATGGCGAAC. ß-
actin gene was used as endogenous control. To evaluate if the ß-
actin gene was suitable as endogenous control, we performed
quantification using ß-actin, cyclophilin A (NM_008907) mCy-
cloFo343 CAAATGCTGGACCAAACACAA mCycloRe413
Figure 1. Gene targeting strategy to produce the MCT1 knockout/ß-galactosidase knockin mouse. (A) Structure of the MCT1 wildtype
allele, the targeting vector, and the resulting MCT1 knockout/ß-galactosidase knockin allele showing the targeted locus. Exons are represented as
grey boxes except exon 1 that contains the translation initiation codon (ATG). The mct1 gene sequence (640 bp) replaced by the fused LacZ/Neo
gene sequence is indicated in red. TK, thymidine kinase gene for negative selection with Gancyclovir ; ß-Gal, the LacZ gene sequence coding for the
enzyme ß-galactosidase ; Neo, neomycin resistance gene for positive selection with G418. (B) Southern blot performed with a 900 bp probe (green in
A) on selected embryonic cell (ES) DNA digested with NdeI (Nd). ES 1 and 2 cell populations are showing a 7200 nt band corresponding to the
wildtype (WT) allele and a 8800 nt band corresponding to the modified knockin (KI) allele due to a double recombination event. ES 3 and 4 cell
populations did not undergo the double recombination event and only exhibit the 7200 nt band. (C) PCR genotyping strategy. PCR made with the
primers MCT1 Fo, MCT1 Re and ßGal Re (see localization in A) present in the same reaction produces a fragment of 538 nt for wildtype (WT) animals,
but also an additional fragment of 422 nt for heterozygote (HE) animals. (D) Histochemical detection of ß-galactosidase activity in selected tissues of
MCT1+/LacZ mice. The blue color in cells reflects the presence of the ß-galactosidase enzyme and therefore the mct1 promoter activity (arrows). Tissue
counterstaining was done with nuclear fast red dye. EDL, extensor digitorum longus.
doi:10.1371/journal.pone.0082505.g001
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GCCATCCAGCCATTCAGTCT, and HPRT (NM_013556)
mHPRTFo514 GCAGTACAGCCCCAAAATGG,
mHPRTRe598 AACAAAGTCTGGCCTGTATCCAA as other
endogenous controls and used the GeNORM method [22] to
quantify MCT1 expression in different tissues (data not shown). ß-
actin was chosen for the studies as we obtained similar results when
we analyzed our data either with GeNORM procedure or using b-
actin gene only as endogenous control. All primer pairs were
designed to overlap exon-exon junction avoiding contamination
signal from eventual genomic DNA. Primers specificity and
efficiency was tested with various amounts of cDNA. All samples
were analyzed in triplicates. Cycle threshold (CT) values obtained
with SDS2.3 software (Applied Biosystems, Rotkreuz, Switzerland)
were imported in an Excel sheet for calculation.
For the study of hepatic gene expression, Messenger RNA from
liver were extracted using RNeasy mini kit (Qiagen) following
manufacturer’s instruction. Quantification of mRNA was per-
formed using the Nanodrop 1000. One hundred of mRNA were
transcribed using TaqMan reverse transcription reagents (Cat. Nu
N808-0234, Applied Biosystems). Quantitative real-time PCR was
performed on the Viia7 Real Time PCR system (Applied
Biosystems). The Taq polymerase master mix employed was the
Power SYBR Green (Applied Biosystems). 18s was chosen as
endogenous control and data analysis was performed using the
22DDCT method. The primers used for each target gene are
indicated in Table 1.
For western blots, tissue samples were mixed (1:1) with 2 x SDS
gel loading buffer (100 mM Tris-Cl pH 6.8, 200 mM dithiothre-
itol, 4% SDS, 0.1% bromophenol blue, 10% glycerol). Before
loading on gel, samples were heated at 95uC for 5 minutes. Ten
micrograms of protein were loaded onto Invitrogen NuPAGE
10% gel (Invitrogen, Basel, Switzerland; Cat Nu NP0301BOX).
Gels were run at 100 Volts and at 4uC. Proteins were transferred
from gels on
Protran BA83 Nitrocellulose membranes (Whatman, Bottmin-
gen, Switzerland; ref. 84261514) using the following transfer
buffer: 0.4 M glycine, 0.25 M Tris-base pH 6.8, 20% methanol.
Transfers were completed by application of 75 Volts during 80
min at 4uC. Membranes were then left for 1 hour at ambient
temperature in 1x PBS containing 0.1% Tween 20 and 2% of
blocking reagent from ECL advance WB detection kit (GE
Healthcare, Piscataway, NJ, USA). The primary antibody was left
overnight at 4uC in the same blocking buffer diluted at 1:2000 for
anti-MCT1 (Novus Biologicals, Littleton, CO, USA; cat. nu
H000006566-B01P) and 1:20000 for anti-ß-actin (Sigma, Buchs,
Switzerland; cat. nu A5441). After washing, the secondary
antibody anti-mouse (1:10000) horseradish peroxidase conjugate
(GE Healthcare, Piscataway, NJ, USA) was applied for one hour at
ambient temperature. Luminescence detection was performed by
following manufacturer’s instructions (GE Healthcare, Piscataway,
NJ, USA) for the ECL advance WB detection kit. Images were
acquired using the Chemidoc XRS system (Bio-Rad, Reinach,
Switzerland). Band intensities quantification was done with the
Quantity One software (Bio-Rad, Reinach, Switzerland).
Histological analysis
Animals were anesthetized with isoflurane before being killed by
cervical dislocation. An incision in the skin was made from rectum
to the oesophagus and the entire animal was put in a buffered
formol fixating solution for 24 hours. Various tissues and organs
were dissected, paraffin-embedded with a Leica ASP300S tissue
processor (Leica, Heerbrug, Switzerland) and 3 mm tissue sections
prepared with a Microm HM 335 E microtome (Thermo
Scientific, Walldorf, Germany). Each section was stained with
hematoxylin and eosin standard procedure, mounted on glass
slides and examined with a Nikon Eclipse 80i microscope (Nikon
AG, Egg, Switzerland) using brightfield optics at 40x magnifica-
tion. Digital images of representative sections were made for
illustrative purposes. For subcutaneous, perigonadal and inguinal
white adipose tissues, each one was dissected immediately after
sacrifice of the animal and fixed in a 4% paraformaldehyde
solution for 24 hours. After being paraffin-embedded, 40 mm
sections were prepared with a microtome and stained with
hematoxylin and eosin. Sections mounted on glass slides were
examined in the same manner as the other tissue sections.
Morphological, behavioural and functional phenotyping
A modified primary SHIRPA protocol was performed on
MCT1+/+ and MCT1+/2 mice [23]. Briefly, mice were observed
during a five minutes period in a jar for spontaneous activity, body
position, respiration and tremor. Then mice were transferred to an
arena (a clean rat cage) where transfer arousal, palpebral closure,
piloerection, gait, pelvic elevation, tail elevation, touch escape,
postural passivity, and shock hearing were monitored. The
Table 1. Sets of primers used for qRT-PCR of genes involved
in lipid metabolism.
Genes Sequence
ACC1 forward 59- TGGTGCAGAGGTACCGAAGTG -39
reverse 59- CTGCGGCAGCAGATCCAT -39
ACC2 forward 59- AACTCCCTGCCAAGCTCATG -39
reverse 59- GCGGCTGTCCAGTTGGTTT -39
FAS forward 59- AGGCTGGGCTCTATGGATTA -39
reverse 59- AAAAGGAGGCGTCGAACTTG -39
DGAT1 forward 59- TTCCGCCTCTGGGCATT -39
reverse 59- AGAATCGGCCCACAATCCA -39
DGAT2 forward 59- AGTGGCAATGCTATCATCATCGT -39
reverse 59- AAGGAATAAGTGGGAACCAGATCA -39
ADRP forward 59- GACCTTGTGTCCTCCGCTTAT -39
reverse 59- CAACCGCAATTTGTGGCTC -39
HSL forward 59- ACGGCGGCTGTCTAATGTC -39
reverse 59- AAACTACGGTATCCGTTGGCT -39
FAT/CD36 forward 59- TCCCCCTACTAGAAGAAGTGGG -39
reverse 59- TCCAACAGATTGGTTTCGTTC -39
CPT1 forward 59- CTCCGCCTGAGCCATGAAG -39
reverse 59- CACCAGTGATGATGCCATTCT -39
LCAD forward 59- TGGCATCAACATCGCAGAGA -39
reverse 59- ACGCTTGCTCTTCCCAAGTAAC -39
ACO forward 59- CCAATGCTGGTATCGAAGAATG -39
reverse 59- GGAATCCCACTGCTGTGAGAA -39
UCP2 forward 59- TCCCCTGTTGATGTGGTCAA -39
reverse 59- CAGTGACCTGCGCTGTGGTA -39
SREBP1c forward 59- GGAGCCATGGATTGCACATT -39
reverse 59- GGCCCGGGAAGTCACTGT -39
PPARgamma forward 59- GGAAGACCACTCGCATTCCTT -39
reverse 59- GTAATCAGCAACCATTGGGTCA -39
18s forward 59- GTAACCCGTTGAACCCCATT -39
reverse 59- CCATCCAATCGGTAGTAGCG -39
doi:10.1371/journal.pone.0082505.t001
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following parameters were evaluated above the arena by taking the
animal by the tail: trunk curl, limb grasping, visual placing, grip
strength. The animal was then held by the tail but kept on the
ground to check pinna reflex, corneal reflex, toe pinch and skin
colour. The animal was held firmly to measure the body length,
lacrimation, salivation, provoked biting, abdominal tone, coat
colour, and pressure resistance on the left leg. Other tests that were
performed include: wire manoeuvre, reflex positioning, negative
geotaxis. During testing, fear, irritability, aggression, scream and
coat tenseness were rated. The coat hanger test, measured grip
strength (Harvard Apparatus, Les Ulis, France) and a rotarod test
with a fix speed (Harvard Apparatus, Les Ulis, France) were
performed. Body temperature was also recorded.
Diet studies/body weight evaluation
MCT1+/2 and MCT1+/+ littermates were individually housed
and received either a normal chow diet (NC) containing 4.5% fat
(Provimi Kliba, Penthalaz, Switzerland; Cat nu 3436) or a high fat
diet (HFD) in which 54.8% of calories are provided by fat (Harlan
Teckland, Oxon, UK; Cat Nu TD.93075) with unlimited access to
food and water from five weeks of age. Body weight was
determined weekly.
Intraperitoneal glucose and insulin tolerance tests
After a 15 hours overnight fasting or a 5 hours fasting
respectively, mice received D-glucose (1 mg/g of body weight;
Applichem Gmbh, Darmstadt, Germany) or insulin (0.3 mU/g of
body weight ; Novo Nordisk A/S, Bagsvaerd, Denmark) by
intraperitoneal injection. Glucose concentrations were measured
at 0, 15, 30, 60 and 120 min after glucose or insulin injection in
blood samples obtained from tail-tip bleedings, using a Gluc-
ometer (Glucotrend Premium, Boehringer, Ingelheim, Germany).
Areas under the curve (AUCs) were measured from 0 to 120
minutes, after subtraction of basal glycemia from each time point.
Body composition
Body composition (fat mass) was determined on isoflurane
anaesthetized MCT1+/2 and MCT1+/+ mice using an Echo MRI
analyzer (Whole Body Composition Analyzer, Echo medical
systems, Houston, TX, USA). Each mouse was weighed before
body composition analysis. Each measurement was performed
twice, and the mean value was reported. Moreover, subcutaneous,
perigonadal, and inguinal white adipose tissues as well as the liver
were removed at the end of the experiment and weighed prior to
be fixed for histological analysis.
Food intake
Mice were provided weekly with food that was weighed and
recorded. Food consumption was manually monitored weekly for
each mouse by subtracting the amount of food remaining (food
compartment + spillage in cage bedding). Individual body weight
was also determined weekly.
Stool energy content
Feces were collected, dried to a constant weight (6 0.001 g) at
60uC, and mean energy content (kJ/g) was determined for each
mouse using a bomb calorimeter (IKA C200, Staufen, Germany).
Physical activity and indirect calorimetry
Spontaneous locomotor activity (horizontal and vertical move-
ments), oxygen consumption, and CO2 production were simulta-
neously determined for 16 mice per experiment, by indirect, open-
circuit calorimetry, in an Oxymax Metabolic Chamber system
(Columbus Instruments, Columbus, OH, USA). A total of 102
measurements/mouse/24 hours was recorded. Adult mice (8–14
weeks old for NC and 14–19 weeks old for HFD) were monitored
for 120 hours but only the last 72 hours of each experimental run
was used for data analysis (n = 8 for both genotypes).
Blood analysis
MCT1+/+ (n = 5) and MCT1+/2 (n = 7) mice maintained on
normal chow diet and MCT1+/+ (n = 4) and MCT1+/2 (n = 8) mice
maintained on high fat diet for 3 months were anesthetized with
pentobarbital by i.p. injection and blood samples were collected
from cardiac puncture. Plasma chemistry was analyzed using the
Roche/Hitachi 902 robot system (Roche). Plasma insulin and
leptin were determined using the mouse metabolic Milliplex kit
(MMHMAG-44k, Merck Millipore) following manufacturer’s
instructions and were quantified on a Luminex MAGPIX
(Luminex Corporation). All samples were measured in duplicate.
Results were analyzed with the Milliplex analyst software (ver.
3.5.5.0, Merck Millipore).
Statistics
All values are expressed as mean 6 SEM. Statistical analyses
were performed using either (where appropriate) a Student’s t-test
or an analysis of variance (ANOVA) followed by a Tukey HSD or
Bonferroni post hoc test with the following levels of significance:
* = P,0.05, ** = P,0.01 and *** = P,0.001.
Results
MCT12/2 mice die at an early embryonic stage but
MCT1+/2
mice are viable
A transgenic mouse was produced by disruption of the mct1
locus. Replacement of a 640 bp sequence including the first exon
within the mct1 gene by a sequence coding for ß-galactosidase
(LacZ gene) in frame with the mct1 promoter was obtained by
homologous recombination (Fig. 1A). Successful recombination
was verified by Southern Blot on selected embryonic stem (ES) cell
DNA. The presence of a 8800 nt band after digestion of DNA with
the restriction enzyme NdeI (Nd) indicated the presence of the
modified allele in some ES cell populations (Fig. 1B). Identification
of transgenic animals was performed by PCR using specific
primers that gave rise to a 422 nt band for the modified allele and
a 538 nt band for the wildtype allele (Fig. 1C). No homozygous
animal (referred to as MCT12/2 or MCT1LacZ/LacZ) was ever
identified among all newborns that were analyzed. Attempts to
determine whether homozygous embryos died before birth
suggested that their development must have been halted quite
early as no homozygote embryo was ever observed. Among
newborns, the ratio of males vs. females was the same. Only male
mice were included in the experiments reported herein.
In order to verify that the transgene introduced in the mct1 locus
was properly inserted and expressed, sections of tissues known for
either high (e.g. brain) or low (e.g. EDL muscle) MCT1 expression
were incubated with the ß-galactosidase substrate X-gal. Blue
deposits indicating the presence of the active enzyme could
be observed in the brain, the heart and the soleus muscle of
MCT1+/LacZ mice while it was not detected in the extensor digitorum
longus (EDL) muscle (Fig. 1D). No staining was seen in tissues from
MCT1+/+ animals (data not shown).
Assessment of MCT1 mRNA expression in selected tissues was
performed in both MCT1+/2 and MCT1+/+ mice and reported as
relative expression. A significant reduction of MCT1 mRNA levels
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was observed in brain, spinal cord, EDL and soleus muscles, heart
as well as brown adipose tissue (BAT) of MCT1+/2 mice compared
to MCT1+/+ animals (Fig. 2A). Decrease in expression ranges from
20% (liver) to almost 80% (EDL muscle). Determination of MCT1
protein levels in the same tissues by western blot (Fig. 2B) revealed
a significant reduction of approximately 50% in brain, spinal cord,
EDL and soleus muscles, heart as well as BAT of MCT1+/2 mice
compared to MCT1+/+ mice (Fig. 2C). Histological analysis of
several tissues (Fig. 2D and Fig. S1) did not reveal striking
structural differences between MCT1+/+ and MCT1+/2 mice. A
further morphological, behavioral and functional assessment of the
MCT1+/2 mouse phenotype was performed using the SHIRPA
protocol [23]. Except for the body length (nose-to-anus), other
parameters were within normal range (Table S1).
MCT1+/2 mice exhibit resistance to diet-induced obesity
as well as to associated glucose intolerance and insulin
resistance
MCT1+/2 mice were almost undistinguishable morphologically
from MCT1+/+ mice (Fig. 3A, upper panel). Comparison of body
weight evolution under normal chow diet (NC) revealed a similar
Figure 2. MCT1 mRNA and protein expression levels in tissues fromMCT1+/+ vs.MCT1+/2mice and comparative histological analysis.
(A) Quantitative RT-PCR analysis of relative MCT1 mRNA levels in tissues collected from MCT1+/2 and MCT1+/+ mice. Values are expressed as
percentage and represent the mean normalized MCT1 mRNA level in MCT1+/2 mouse tissue compared to the mean normalized MCT1 mRNA level in
MCT1+/+ mouse tissue 6 SEM, n = 6. ß-actin mRNA was used as reference. Statistical analysis was performed using the Student’s t-test. Asterisks
indicate a significant difference between heterozygote and wildtype tissues. *P,0.05, ** P,0.01. (B) Representative western blot performed on
protein extracts from selected tissues of MCT1+/+ and MCT1+/2 mice. ß-actin was used as reference for quantification. (C) Quantitative analysis of
MCT1 protein expression. Values are expressed as percentage, and represent the mean normalized MCT1 protein level of MCT1+/2 mice compared to
the mean normalized MCT1 protein level for MCT1+/+ mice 6 SEM, n = 6. Statistical analysis was performed using the Student’s t-test. Asterisks
indicate a significant difference between heterozygote and wildtype tissues. *P,0.05, ** P,0.01. (D) Comparative histological analysis of selected
tissues from MCT1+/+ and MCT1+/2 mice. Sections from brain (cortex), heart, skeletal muscle (mixed type), liver, and white adipose tissue (WAT) of
both MCT1+/+ and MCT1+/2 mice were stained with hematoxylin/eosin and examined under light microscopy at 40x magnification. Calibration bar,
100 mm.
doi:10.1371/journal.pone.0082505.g002
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rate of body weight gain between MCT1+/+ and MCT1+/2 mice
(Fig. 3A, lower panel). Although body weight of MCT1+/2 mice
was slightly lower (due to a slightly smaller body length), this initial
difference was maintained over the entire period studied. When
fed a high fat diet (HFD), MCT1+/+ mice gained considerable
weight and became obese (Fig. 3B, upper panel). In contrast,
MCT1+/2 mice fed the same diet remained leaner. An evaluation
of body weight gain over time for mice put under HFD starting at
5 weeks of age clearly shows that MCT1+/2 mice increased their
body weight at a much lower rate than MCT1+/+ mice (Fig. 3B,
lower panel). After 16 weeks under HFD, the difference in body
weight reached on average 24.8% less for MCT1+/2 mice
compared to MCT1+/+ mice (31.862.2 g vs. 42.362.8 g respec-
tively, P,0.05).
An important consequence of obesity is the development of
insulin resistance. To evaluate this parameter, MCT1+/2 and
MCT1+/+ mice fed NC or HFD were metabolically challenged. An
intraperitoneal glucose tolerance test (IpGTT) was performed on
13 weeks-old MCT1+/2 and MCT1+/+ mice previously fed for 8
weeks either NC or HFD (Fig. 4A). Blood glucose levels under
fasting conditions prior to glucose load (0 minute) were similar
between MCT1+/2 and MCT1+/+ mice (5.660.3 vs. 5.960.2 mM
respectively, P=0.393 for NC condition; 5.360.2 vs.
6.360.2 mM respectively, P=0.084, for HFD condition). The
glycemic excursion in response to a glucose load was not different
between MCT1+/2 and MCT1+/+ mice when fed NC (Fig. 4A, left
panel; Inset: area under the curve = 996669 vs. 1127616 mM/
minute respectively, P=0.145). In contrast, when fed HFD, the
glycemic excursion was lower in MCT1+/2 mice compared to
MCT1+/+ mice, indicating higher glucose tolerance (Fig. 4A, right
panel; Inset: area under the curve = 22086178 vs.
29006179 mM/minute respectively, P,0.05).
Insulin sensitivity was investigated 1 week later with an insulin
tolerance test (ITT) on the same MCT1+/2 and MCT1+/+ mice
previously fed either NC or HFD (Fig. 4B). The glycemic drop
following insulin administration did not differ between MCT1+/2
and MCT1+/+ mice under NC (Fig. 4B, left panel). However, when
the experiment was performed on mice fed HFD, the insulin-
induced glycemic drop was more pronounced for MCT1+/2 mice
than for MCT1+/+ mice indicating a better insulin sensitivity (Fig.
4B, right panel). Moreover, the difference in blood glucose levels
remained between the two groups of mice for the duration of the
experiment (120 minutes).
Less fat accumulation in liver and white adipose tissue
accounts for lower body weight gain in MCT1+/2 mice
under HFD
An analysis of body composition (to determine fat mass) by
magnetic resonance proton spectroscopy (EchoMRI) was per-
formed on MCT1+/2 and MCT1+/+ mice previously fed either NC
or HFD (Fig. 5A). Results revealed that the body fat content of
MCT1+/2 mice is slightly but significantly lower than in MCT1+/+
Figure 3. Body weight gain for MCT1+/+ and MCT1+/2 mice fed a normal chow or high fat diet. (A) Photograph of representative MCT1+/+
and MCT1+/2 mice fed with a normal chow diet for 12 months (upper panel). Weight gain over time for MCT1+/+ and MCT1+/2 mice fed with a normal
chow diet (lower panel). (B) Photograph of representative MCT1+/+ and MCT1+/2 mice fed with a high fat diet for 12 months (upper panel). Weight
gain over time forMCT1+/+ and MCT1+/2mice fed starting at 5 weeks of age with a high fat diet (lower panel). +/+,MCT1+/+; +/-,MCT1+/2. Filled circles,
MCT1+/+; open circles, MCT1+/2. Results are mean 6 SEM, n = 7.
doi:10.1371/journal.pone.0082505.g003
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mice when fed NC for 2 months (2.2360.27 g vs. 3.0860.24 g
respectively; P,0.05). When fed with HFD for 2 months, fat
mass increased in both genotypes but less in MCT1+/2 than in
MCT1+/+ mice (3.1960.32 g vs. 5.9460.98 g respectively;
P,0.05). Expressed as percentage of total body weight,
MCT1+/2 mice exhibited 12.8461.06% body fat while MCT1+/
+ mice had 19.4162.31%. Mice fed during 9 months under HFD
showed an important difference in fat mass between genotypes
that reached more than 10 g (10.961.6 vs. 21.860.7 g for
MCT1+/2 and MCT1+/+ respectively; P,0.001). Reported to
body weight, fat represented 29.263.0% in MCT1+/2 mice and
42.060.5% for MCT1+/+ mice.
To gain further insight about alterations of body composition,
MCT1+/+ and MCT1+/2 mice fed HFD for 11 months were
dissected to collect several organs and tissues. Visual inspection
revealed a difference in size of the liver and adipose tissue.
Weighing confirmed that liver from MCT1+/+ mice was almost
40% heavier (Table 2). When comparing adipose tissue from
different locations, some differences also emerged (Table 2).
Subcutaneous and perigonadal white adipose tissues (WAT) from
MCT1+/2 mice weigh significantly less. In contrast, no difference
was observed for the inguinal WAT. Consistent with the visual
inspection, observation of stained liver sections from MCT1+/+
mice revealed an important hepatic steatosis (Fig. 5B, upper left
panel). In contrast, liver fromMCT1+/2mice appeared completely
normal (Fig. 5B, upper right panel). A comparison of sections from
subcutaneous WAT between MCT1+/2 and MCT1+/+ mice
suggests that adipocytes are smaller in MCT1+/2 mice (Fig. 5B).
No such difference was detected for perigonadal and inguinal
WAT (Fig. 5B). Other tissues from MCT1+/2 mice maintained on
HFD appeared normal (Fig. S2).
Figure 4. Glucose homeostasis in MCT1+/+ and MCT1+/2mice fed a normal chow or high fat diet. (A) Intraperitoneal glucose tolerance test
in MCT1+/+ and MCT1+/2 mice fed with a normal chow (left panel) or with a high fat diet (right panel) for 8 weeks. Inset: Quantitative analysis of
integrated glycemic responses (as area under the curve or AUC). Filled bar, MCT1+/+ mice. Open bar, MCT1+/2 male mice (B) Intraperitoneal insulin
tolerance test in MCT1+/+ and MCT1+/2mice fed with a normal chow (left panel) or with a high fat diet (right panel) for 8 weeks. Filled circles,MCT1+/+;
open circles, MCT1+/2. Results are mean 6 SEM, n = 5–9. Asterisks represent a statistically significant difference between MCT1+/+ and MCT1+/2 mice
evaluated using a Student’s t-test. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0082505.g004
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Lower food intake and intestinal absorption combined
with higher metabolic rate contribute to lesser body
weight gain in MCT1+/2 mice under HFD
Modifications of energy intake and/or expenditure could
explain the differences in weight gain observed between
MCT1+/2 and MCT1+/+ mice when fed HFD. Food intake was
examined in MCT1+/2 and MCT1+/+ mice but under NC, no
significant difference was observed (data not shown). Under HFD
however, distinct patterns emerged as MCT1+/+ mice started to
gain weight at a higher rate than MCT1+/2 mice from the third
week under HFD (Fig. 6A). Reported as cumulated body weight
gain, it can be seen that the difference becomes highly significant
from the third week under HFD (Fig. 6B). When food intake is
plotted, 2 phases can be distinguished (Fig. 6C). A rapid decrease
in food intake occurs in the first 2 weeks, followed by stabilization
in the amount of food ingested. MCT1+/2 mice maintained on
HFD exhibited from the third week onward a lower food intake
than MCT1+/+ mice. The difference can be even better
appreciated when data are reported as cumulated food intake,
clearly showing that MCT1+/2 mice had a lower quantity of
ingested food compared to MCT1+/+ mice (Fig. 6D). Interestingly,
the appearance of food intake difference correlates with the
divergence of body weight between MCT1+/2 and MCT1+/+ mice
(compare Fig. 6A with 6C). Intestinal absorption also determines
the amount of energy intake by the organism. To evaluate
intestinal absorption, stool energy content for both MCT1+/2 and
MCT1+/+ mice under HFD was determined. Indeed, MCT1+/2
mice exhibited a 9.6% higher stool energy content than MCT1+/+
mice (175966323 vs. 160556264 J/g of stool, P,0.01). Thus,
both hypophagia and reduced energy assimilation are key
contributors to the resistance to diet-induced obesity in HFD-fed
MCT1+/2 mice.
Energy expenditure components include the metabolic rate and
physical activity. Energy homeostasis was assessed using the
Comprehensive Laboratory Animal Monitoring System
(CLAMS). Locomotor activity was evaluated by recording both
horizontal and vertical movements over a period of 3 days and by
reporting the cumulated data for the diurnal and nocturnal
periods. No significant difference was observed between MCT1+/2
and MCT1+/+ mice when fed either NC or HFD (Fig. 7A, B).
Indirect calorimetry was used to assess the metabolic rate by
measuring both oxygen consumption (VO2) and carbon dioxide
production (VCO2) over a period of 3 days. No significant
Figure 5. Fat mass accumulation and distribution in MCT1+/+
and MCT1+/2 mice fed a normal chow or high fat diet. (A) Fat
mass changes in MCT1+/+ and MCT1+/2 mice fed a normal chow or a
high fat diet for different periods of time. Results are mean 6 SEM,
n = 4-9. Asterisks represent a statistically significant difference between
MCT1+/+ and MCT1+/2 mice evaluated using a Student’s t-test. *P,0.05,
***P,0.001. +/+, MCT1+/+; +/-, MCT1+/2; NC, normal chow; HFD, high fat
diet; 2 m, 2 months; 9 m, 9 months. (B) Comparative histological
analysis of liver and distinct adipose tissues of MCT1+/+ and MCT1+/2
mice fed a high fat diet for 11 months. ScWAT, subcutaneous white
adipose tissue; PgWAT, perigonadal white adipose tissue; IgWAT,
inguinal white adipose tissue. Calibration bar, 100 mm.
doi:10.1371/journal.pone.0082505.g005
Table 2. Body, liver and white adipose tissues mass of HFD
fed mice.
MCT1+/+ (7) MCT1+/2 (4)
Body weight (g) 55.261.0 44.362.6***
Liver (g) 4.2760.20 2.6560.39**
ScWAT (g) 1.8760.14 1.1660.13**
PgWAT (g) 3.8460.24 2.9860.25*
IgWAT (g) 0.6960.06 0.6460.11
Results are expressed as mean 6 SEM ; values within parentheses indicate
number of mice. *P,0.05, **P,0.01, ***P,0.001 by Student’s t-test. ScWAT,
Subcutaneous white adipose tissue; PgWAT, Perigonadal white adipose tissue;
IgWAT, Inguinal white adipose tissue.
doi:10.1371/journal.pone.0082505.t002
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difference in either oxygen consumption or carbon dioxide
production was observed between MCT1+/2 and MCT1+/+ mice
fed NC (Fig. 7C). When fed HFD for 9 weeks however, MCT1+/2
mice consumed 15% more oxygen (VO2 = 93006264 vs.
80526221 ml.kg–1.h–1 respectively; P,0.01) and consequently
produced 15% more carbon dioxide VCO2= 76626192 vs.
66466150 ml.kg–1.h–1 respectively; P,0.01) than MCT1+/+ mice
during daytime, but not during nighttime (Fig. 7D). In addition,
respiratory quotients were calculated in all cases. Under normal
chow, no significant difference was observed between MCT1+/2
and MCT1+/+ mice during daytime (0.9260.01 vs. 0.9460.01
respectively; P=0.32) or nighttime (1.0560.01 vs. 1.046x1025
respectively; P=0.376). When animals were fed HFD, respiratory
quotient values decreased for all conditions, but no significant
difference was observed between MCT1+/2 and MCT1+/+ mice
during daytime (0.8360.01 vs. 0. 8360.01 respectively; P=0.91)
while a very small but significant difference was detected during
nighttime (0.856161025 vs. 0.836161025 respectively; P,0.05,
corresponding to 49% vs. 42% of carbohydrate consumption).
Attenuated alterations in some circulating hormone
levels and in hepatic lipid metabolism are distinctive
features of HFD-fed MCT1+/2 mice
In order to gain further insight about the putative molecular
mechanisms that could explain the observed phenotype in
MCT1+/2 mice, the plasma content of several metabolites and
hormones was analyzed in both MCT1+/2 and MCT1+/+ mice
under either normal chow or HFD for four months (Table 3).
Figure 6. Body weight gain and food intake for MCT1+/+ and MCT1+/2 mice fed high fat diet. (A) Evolution with time of body weight (B)
Cumulative body weight gain (C) Weekly measured food intake (D) Cumulative food intake. Results represent mean 6 SEM, n = 10–11. Filled circles,
MCT1+/+ mice; open circles, MCT1+/2 mice. The asterisk represents a statistically significant difference between MCT1+/+ and MCT1+/2 mice evaluated
using a Student’s t-test for each pair of data under the dotted line. *P,0.05.
doi:10.1371/journal.pone.0082505.g006
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Under normal chow, no significant differences were observed for
most parameters tested, except for lactate that was higher in
MCT1+/2 mice and triglycerides that were lower in MCT1+/2
mice. Under HFD however, several parameters were differentially
affected. Triglycerides were still lower in MCT1+/2 mice although
the difference did not reach significance. The plasma level of the
enzyme alanine aminotransferase (ALAT; a marker of hepatocel-
lular injury) was lower in MCT1+/2 mice. Interestingly, the levels
of insulin and leptin, which were increased in MCT1+/+ mice
under HFD compared to normal chow, were significantly lower in
MCT1+/2 mice under HFD. When the HOMA (homeostasis
model assessment) index was calculated (an indication of insulin
resistance), a similar observation was made with a significantly
lower value in MCT1+/2 mice under HFD compared to MCT1+/+
mice.
Although differences of MCT1 expression were observed in
several organs and tissues between MCT1+/2 and MCT1+/+ mice
fed a normal chow (Fig. 2A-C), this pattern might not be the same
when animals are exposed to HFD for a prolonged period. For this
reason, both MCT1 mRNA and protein expression was re-
examined in the same organs and tissues but after three months
under HFD (Fig. 8). Indeed, although some features remained (e.g.
lower expression in MCT1+/2 brain and heart), new ones
emerged. This is the case for the liver that did not exhibited any
difference under normal chow but in which MCT1 expression
became lower in MCT1+/2 mice compared to MCT1+/+ mice
under HFD, both at the mRNA (Fig. 8A) and at the protein level
(Fig. 8B, C). These observations prompted us to examine in the
liver the expression of various genes involved in lipid metabolism
between MCT1+/2 and MCT1+/+ mice under either normal chow
or HFD for three months (Fig. 9). Genes could be grouped into
different categories, being involved either in lipid synthesis (i.e.
ACC1, ACC2, FAS, DGAT1, DGAT2), storage (i.e. ADRP),
release (i.e. HSL), transport (i.e. FAT/CD36, CPT1), oxidation
(i.e. LCAD, ACO, UCP2) or in regulation of lipid metabolism (i.e.
SREBP1c, PPARgamma). Quite remarkably, three months under
high fat diet led to an enhancement of mRNA expression for all
genes involved in lipid metabolism investigated in the liver of
MCT1+/+ mice. In contrast, in the liver of MCT1+/2 mice, either
no enhancement or a much reduced level of mRNA expression
compared to MCT1+/+ mice was observed for the same genes
following HFD.
Discussion
The MCT1 null mouse exhibits an embryonic lethal phenotype,
restricting possibilities to study MCT1 functions in this species.
Interestingly, an MCT1 ortholog called Silnoon has been identified
in Drosophila melanogaster and various loss-of-function mutants have
been generated [24]. Similarly to our MCT1 null mouse, the
homozygous fly mutant for Silnoon exhibited early larval lethality.
This observation suggests that the use of monocarboxylates is
Figure 7. Locomotor activity and indirect calorimetry for MCT1+/+ and MCT1+/2 mice fed a normal chow or high fat diet. (A) Vertical
and horizontal movements of MCT1+/+ and MCT1+/2 mice under normal chow. (B) Vertical and horizontal movements of MCT1+/+ and MCT1+/2 mice
under high fat diet. Filled bars, MCT1+/+ mice; open bars, MCT1+/2 mice. (C) O2 consumption and CO2 production of MCT1
+/+ and MCT1+/2 mice fed a
normal chow. (D) O2 consumption and CO2 production of MCT1
+/+ and MCT1+/2 mice fed a high fat diet. VO2, oxygen consumption ; VCO2, carbon
dioxide production. Filled bars, MCT1+/+ mice; open bars, MCT1+/2 mice. Results represent mean 6 SEM, n= 5-8. Asterisks represent a statistically
significant difference between MCT1+/+ and MCT1+/2 mice evaluated using a Student’s t-test. **P,0.01.
doi:10.1371/journal.pone.0082505.g007
Table 3. Plasma biochemical profile of MCT1+/+ and MCT1+/2 mice fed a normal chow or a high fat diet.
Normal chow High Fat Diet
Plasma parameter MCT1+/+ (5) MCT1+/2 (7) MCT1+/+ (7) MCT1+/2 (12)
Glycemia (mg/dL) 161.866.3 140.065.7 177.5614.8 162.364.5
Ketone bodies (mM) 0.2260.02 0.2160.03 0.3160.05 0.3160.03
Lactate (mM) 5.160.5 7.060.7* 4.560.5 3.760.3
Cholesterol (mM) 2.760.2 2.560.1 4.160.6 3.660.3
HDL (mM) 1.560.1 1.660.1 2.660.4 2.460.2
LDL (mM) 0.2560.06 0.2360.02 0.3460.06 0.3360.03
Triglycerides (mM) 1.860.4 1.160.1* 1.460.1 0.9260.07
FFA (mM) 0.4160.05 0.3960.05 0.7260.08 0.5860.06
Lipase (mM) 53.763.5 52.464.3 53.162.1 71.469.3
LDH (U/L) 1381.66267.1 1128.36228.8 1940.36225.5 1631.86121.2
ALAT (U/L) 36.662.7 50.766.9 150.3639.2 83.7612.7*
ASAT (U/L) 213.8646.7 210.5651.7 534.96135.1 469.2646.5
Ghrelin (ng/mL) 2.7160.66 1.3960.42 1.5760.25 2.2060.40
Leptin (ng/mL) 0.7060.08 0.7460.19 15.5861.99 4.7260.72***
Insulin (ng/mL) 1.46960.390 1.98660.482 6.40061.848 2.16760.496*
HOMA index 0.74460.207 1.04660.263 3.09760.888 0.89560.233**
Results are expressed as mean 6 SEM; values within parentheses indicate number of mice. *P,0.05, **P,0.01, ***P,0.001 vs. MCT1+/+ on the same diet with two-way
ANOVA followed by Bonferroni post hoc test. HDL, High density lipoprotein; LDL, Low density lipoprotein; FFA, Free fatty acids; LDH, Lactate dehydrogenase; ALAT,
Alanine aminotransferase; ASAT, Aspartate aminotransferase; HOMA, Homeostasis model assessment.
doi:10.1371/journal.pone.0082505.t003
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Figure 8. MCT1 mRNA and protein expression levels in tissues from MCT1+/+ vs. MCT1+/2 mice following three months of high fat
diet (A) Quantitative RT-PCR analysis of relative MCT1 mRNA levels in tissues collected from MCT1+/2 and MCT1+/+ mice. Values are
expressed as percentage and represent the mean normalized MCT1 mRNA level in MCT1+/2 mouse tissue compared to the mean normalized MCT1
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crucial for early growth and development in different species. It is
noteworthy that abundant placental MCT1 expression was
reported, as early as gestational day 11.5 in mice [25]. In this
context, placental MCT1 expression might play a key role in the
transfer of monocarboxylates from the maternal circulation and
ensure proper substrate supply for embryonic development. It is
purported that absence of placental MCT1 expression might be a
cause of early lethality.
In the absence of a viable null mutant, the MCT1+/2 mouse was
further investigated. The phenotype observed was mild with no
marked morphological or behavioural alteration. Similarly, no
obvious changes were observed in any tissue that was examined
histologically. The explanation may lie in the extent of the
reduction of MCT1 expression found in the different tissues
analyzed that never exceeded 50% at the protein level. These
levels of expression might be sufficient to maintain proper function
in most tissues and organs under normal diet. For example, MCT1
knockdown in cultured astrocytes reduced lactate transport but not
stimulated lactate release [26]. However, we can not exclude that
other monocarboxylate transporters might have compensated for
decreased MCT1 expression.
The C57BL/6J mouse strain is sensitive to diet-induced obesity
and represents a good model to study the underlying mechanisms
leading to this condition [27]. Such a vulnerability to the
development of obesity could also be exploited to identify specific
genes that give rise to this susceptibility. Indeed, invalidation of a
subset of genes has been shown to confer at least partial resistance
to diet-induced obesity, e.g. the m opioid receptor [28], the
retinoblastoma protein [29], the peroxisome proliferating-activat-
ed receptor gamma [30], the very-long-chain fatty acid elongase
[31] or the CB1 cannabinoid receptor [32]. These genes have
been qualified of ‘‘thrifty genes’’ as they promote the storage of
energy reserves in time of food abundance, an important function
from an evolutionary point of view. The mct1 gene appears to
belong to this group but represents a new protein class, i.e.
nutrient transporters. In addition, the haploinsufficiency of the
mct1 gene in regard to body weight regulation is noteworthy.
Indeed, it is useful to point out that body weight regulation is also
influenced in the case of haploinsufficiency of genes involved in the
development of monogenetic obesity such as the leptin gene or the
POMC gene [33,34]. Accordingly, such a characteristic seems to
further emphasize the critical role played by these genes in energy
homeostasis.
Our investigation to determine which parameter(s) of the energy
balance influenced by MCT1 expression affect(s) body weight gain
under HFD has revealed alterations in energy intake. Although no
difference in food intake was observed between MCT1+/2 and
MCT1+/+ mice when fed NC, a more important reduction in food
intake occurred in MCT1+/2 mice when switched to HFD.
Control of food intake takes place in the lateral hypothalamus
where the presence of fuel-sensing neurons capable to modify their
firing patterns in response not only to glucose but also to
monocarboxylates has been reported [5]. Moreover, it was
demonstrated that such neurons express the monocarboxylate
transporter MCT1 [5]. One possible explanation for the observed
food intake adaptations is that changes in MCT1 expression levels
on some hypothalamic neurons alters the sensitivity of the circuit
controlling food intake to specific peripheral signals (e.g. insulin,
leptin or ghrelin), whose levels vary in response to HFD. Indeed,
plasma insulin and leptin levels were reduced in MCT1+/2 mice
compared to MCT1+/+ mice, suggesting that sensitivity to these
hormones was likely preserved in MCT1+/2 mice, in contrast to
MCT1+/+ mice. Interestingly, Drosophila mutants for Silnoon (the
MCT1 ortholog) displayed halted food intake [24], which indeed
suggests that MCT1 expression is critical for this function. In
parallel, the higher caloric content of feces observed in MCT1+/2
mice indicates reduced intestinal absorption of some nutrients.
MCT1 is differentially expressed in various parts of the
gastrointestinal tract [19] and it was observed that MCT1
expression on the luminal membrane of intestinal epithelial cells
is critical for the transport of short-chain fatty acids such as
butyrate [35]. Short-chain fatty acids were shown not only to serve
as precursors for lipogenesis [36], but in intestinal cells they also
downregulate expression of genes involved in lipid metabolism,
e.g. cholesterol synthesis [37]. Thus, a reduction in intestinal
MCT1 expression might impact on the capacity of the intestine to
properly extract short-chain fatty acids and might as well modify
intestinal lipid metabolism.
Diet-induced obesity in mice is often characterized by glucose
intolerance, insulin resistance, elevated insulinemia as well as
leptinemia associated with increased fat mass [27,38]. Many
treatments aiming at reducing or preventing the development of
obesity tend to normalize these different parameters [39,40].
Similarly, transgenic mice identified to resist to the development of
diet-induced obesity usually exhibit attenuation or even absence of
these metabolic dysregulations [28,29,31,32]. It seems also to be
the case of HFD fed MCT1+/2 mice. Thus, a greater glucose
tolerance as well as higher insulin sensitivity could be evidenced in
HFD fed MCT1+/2 mice compared to HFD fed MCT1+/+ mice.
Along with the improvement of insulinemia, the insulin resistance
present in HFD fed MCT1+/+ mice was not detected in HFD fed
MCT1+/2 mice. In parallel, fat mass was significantly reduced
while leptinemia returned to almost normal values. Thus, it
appears that haploinsufficiency of the mct1 gene, in parallel of
reducing fat mass accumulation, prevents the emergence of the
main characteristic metabolic dysregulations associated with
obesity. Whether the reduction in fat mass is the sole factor
explaining the normal glucose tolerance, the absence of insulin
resistance as well as almost normal insulinemia and leptinemia
remains to be demonstrated. However, preliminary results about
the relationship between fat mass and insulin resistance (Fig. S3)
suggest that under high fat diet, others factors might also
contribute to the metabolic dysregulations observed. Indeed, it
was previously shown that factors such as inflammation,
lipotoxicity or gut microbial dysbiosis can also participate to the
development of insulin resistance, in association or not with
increased fat mass [41].
Prevention of hepatic steatosis and reduction in adiposity are
important features of MCT1+/2 mice under HFD, and these are
common traits among animal models exhibiting resistance to diet-
induced obesity. Modifications in fat and/or glucose metabolism,
as documented by changes in expression of genes related to their
mRNA level in MCT1+/+ mouse tissue 6 SEM, n = 4 (MCT1+/+) and 7 (MCT1+/2). ß-actin mRNA was used as reference. Statistical analysis was performed
using the Student’s t-test. Asterisks indicate a significant difference between heterozygote and wildtype tissues. *P,0.05, **P,0.01, ***P,0.001. (B)
Representative western blot performed on protein extracts from selected tissues of MCT1+/+ and MCT1+/2 mice. ß-actin was used as reference for
quantification. (C) Quantitative analysis of MCT1 protein expression. Values are expressed as percentage, and represent the mean normalized MCT1
protein level of MCT1+/2 mice compared to the mean normalized MCT1 protein level for MCT1+/+ mice 6 SEM, n = 4 (MCT1+/+) and 7 (MCT1+/2).
Statistical analysis was performed using the Student’s t-test. Asterisks indicate a significant difference between heterozygote and wildtype tissues.
*P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0082505.g008
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metabolism, often provide an explanation for the prevention of the
energy imbalance that leads to the observed phenotypic charac-
teristics in diet-induced obese animals. Thus, an enhancement of
fatty acid oxidation occurring in the liver [29] and/or in muscle
[28,29], a decrease of lipogenesis in the liver [31], or alterations of
lipogenesis/lipolysis in the adipose tissue [42,43] are common
findings in these models. In contrast to the upregulation of genes
involved in lipid metabolism in the liver of HFD fed MCT1+/+
mice, an observation in agreement with published observations
[44], the expression of the same genes was relatively unaffected in
the liver of HFD fed MCT1+/2 mice. Thus, no apparent
enhancement in hepatic lipid synthesis and storage capacity is
taking place in MCT1+/2 mice exposed to HFD. These findings
seem corroborated by the tendency toward a reduction in plasma
triglycerides that was detected in HFD fed MCT1+/2 mice
compared to MCT1+/+ mice. Thus, a lack of enhanced lipid
synthesis and storage capacity in the liver could be a plausible
explanation for the prevention of hepatic steatosis and obesity, as
observed in several transgenic mouse models [45]. Indeed, it was
previously shown that inhibition or altered expression of some key
proteins involved in lipogenesis can prevent hepatic steatosis and
dyslipidemia [31,46-48]. In parallel, no enhancement in the
expression of genes involved in fatty acid oxidation could be
evidenced in the liver of HFD fed MCT1+/2 mice, arguing against
an increase in hepatic ß-oxidation. Hence, hepatic fatty acid
oxidation does not appear to contribute to the prevention of
hepatic steatosis, and a fortiori to overall reduced fat mass in HFD
fed MCT1+/2 mice. The question arises about the role of MCT1
per se in the liver in relation with adaptation of lipid metabolism.
Although no difference in MCT1 expression at the mRNA and
protein levels could be detected in the liver betweenMCT1+/2 and
MCT1+/+ mice under normal chow, both MCT1 mRNA and
protein levels were significantly lower in the liver of MCT1+/2
mice fed HFD vs. MCT1+/+ mice fed HFD. It is conceivable then
that MCT1 expression in the liver might have influenced hepatic
lipid metabolism. However, no significant difference in the plasma
levels of MCT1 substrates such as lactate and ketone bodies
between the two genotypes could be observed, which seems to rule
out a reduced capacity to use or produce these substrates, although
we can not exclude a reallocation of these substrates to tissues with
a different MCT subtype expression profile. Nevertheless, our
results revealed that reduced hepatic MCT1 expression under
HFD interfered with the adaptive metabolic response of the liver
to HFD towards lipids, although the mechanism remains for the
moment unclear.
Putative alterations in hepatic liver metabolism suggested by the
uncovered gene expression pattern in animals fed HFD may not
entirely explain the overall reduction in fat mass. Other
mechanisms must be postulated to fully account for this specific
feature. Possible alterations in lipid/glucose metabolism could be
present as well in other tissues including muscle and adipose tissue.
For example, an increase in muscle energy substrate oxidation
could account for the observed enhancement in daytime metabolic
rate. If it is the case however, it does not appear to be due to a shift
in the type of substrates oxidized (i.e. lipids at the expense of
carbohydrates) based on the calculated respiratory quotients, but it
should rather represents simply an overall enhanced oxidation
rate. Increased muscle fatty acid oxidation was previously
implicated in the prevention of diet-induced fat mass accumulation
[28,29,49]. Similarly, we can not exclude that some aspects of
adipose tissue metabolism are affected, including lipid storage and
lipolysis. Indeed, although no difference in MCT1 expression
could be detected between MCT1+/2 and MCT1+/+ mice under
normal chow in white adipose tissue, MCT1 protein levels were
significantly lower in HFD fed MCT1+/2 mice vs. HFD fed
MCT1+/+ mice. Further investigations in both muscle and adipose
tissue will be necessary to assess such possible metabolic
alterations.
In summary, the present work demonstrates that the partial
invalidation of the mct1 gene leads to specific metabolic and
behavioral adaptations preventing the development of diet-
induced obesity, hepatic steatosis and insulin resistance in mice.
Further studies will be necessary to shed light on the precise
mechanisms by which a reduction in MCT1 expression in specific
tissues give rise to the described phenotypical characteristics.
However, our study already provides a proof-of-concept that the
MCT1 transporter represents a new therapeutic target to prevent
and/or treat obesity.
Supporting Information
Figure S1 Comparative histological analysis of various
tissues from MCT1+/+ and MCT1+/2 mice fed a normal
chow. BAT, brown adipose tissue. Calibration bar, 100 mm.
(TIF)
Figure S2 Comparative histological analysis of various
tissues from MCT1+/+ and MCT1+/2 mice fed a high fat
diet. BAT, brown adipose tissue. Calibration bars, 20 or 100 mm.
(TIF)
Figure S3 Relationship between the percentage of fat
mass and the degree of insulin resistance (as evaluated
by the HOMA index) in both MCT1+/+ and MCT1+/2
mice fed either a normal chow or a high fat diet. Filled
circle, MCT1+/+ mouse fed normal chow ; filled triangle,
MCT1+/2 mouse fed normal chow ; Open circle, MCT1+/+
mouse fed high fat diet; Open triangle, MCT1+/2 mouse fed high
fat diet. NC, normal chow diet ; HFD, high fat diet.
(TIF)
Table S1 SHIRPA screening test of MCT1+/+ and
MCT+/2.
(TIF)
Figure 9. Relative liver mRNA expression levels for various genes involved in lipid metabolism from MCT1+/2 and MCT1+/+ mice fed
either normal chow or high fat diet. Quantitative RT-PCR analysis of relative mRNA levels for several genes related to lipid metabolism in liver
collected from MCT1+/2 and MCT1+/+ mice either fed normal chow or high fat diet for three months. Values represent the mean normalized mRNA
level relative to the level found in MCT1+/2 mouse liver fed normal chow (the former given a value of one) 6 SEM, n= 5 (normal chow, MCT1+/+), 7
(normal chow,MCT1+/2) 4 (HFD,MCT1+/+), 8 (HFD,MCT1+/2). Statistical analysis was performed using a two-way ANOVA followed by a Tukey HSD post
hoc test. Asterisks indicate a significant difference between liver samples from wildtype animals under HFD vs. normal chow. *P,0.05, **P,0.01,
***P,0.001. Sharp signs indicate a significant difference between liver samples from heterozygote animals under HFD vs. wildtype animals under
HFD. #P,0.05, ##P,0.01, ###P,0.001. ACC, Acetyl-CoA carboxylase; ACO, Acyl-CoA-oxidase; ADRP, Adipose differentiation-related protein; CPT,
Carnitine palmitoyltransferase; DGAT, diacylglycerol acyltransferase; FAS, Fatty acid synthase; FAT/CD36, Fatty acid translocase; HSL, Hormone-
sensitive lipase; LCAD, Long chain acyl-CoA dehydrogenase; PPAR, Peroxisome proliferator-activated receptor; SREBP, Sterol regulatory element-
binding protein; UCP, Uncoupling protein.
doi:10.1371/journal.pone.0082505.g009
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